Sign In
Buy CRIS
$0.500
-0.0025 (-0.498%)
At Close: Jun 03, 2026
Curis to Present at Upcoming Healthcare Conferences in September
08:00am, Wednesday, 04'th Sep 2024
LEXINGTON, Mass. , Sept. 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi
Curis, Inc. (CRIS) Q2 2024 Earnings Call Transcript
03:44pm, Thursday, 01'st Aug 2024
Curis, Inc. (NASDAQ:CRIS ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President and CEO Jonathan Zung - Chie
Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates
10:10am, Thursday, 01'st Aug 2024
Curis (CRIS) came out with a quarterly loss of $2.03 per share versus the Zacks Consensus Estimate of a loss of $1.70. This compares to loss of $2.40 per share a year ago.
Curis Provides Second Quarter 2024 Financial and Operating Update
08:00am, Thursday, 01'st Aug 2024
EC Grants ODD to emavusertib in PCNSL Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass.
Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
08:00am, Thursday, 25'th Jul 2024
LEXINGTON, Mass. , July 25, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi
Curis to Present at Upcoming Healthcare Conference in July
07:30am, Wednesday, 10'th Jul 2024
LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi
What Makes Curis (CRIS) a New Buy Stock
01:01pm, Tuesday, 09'th Jul 2024
Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:30am, Monday, 08'th Jul 2024
LEXINGTON, Mass. , July 8, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi
Curis Announces Additional Data from TakeAim Leukemia Study
04:00pm, Tuesday, 14'th May 2024
Data update expands AML dataset from 5 to 30 patients LEXINGTON, Mass. , May 14, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-
Curis to Present Updated Data from the TakeAim Leukemia Study
08:00am, Friday, 10'th May 2024
LEXINGTON, Mass. , May 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib
Curis, Inc. (CRIS) Q1 2024 Earnings Call Transcript
08:08pm, Tuesday, 07'th May 2024
Curis, Inc. (NASDAQ:CRIS ) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Diantha Duvall - CFO Jim Dentzer - President & CEO Robert Martell - Chief Scientific Officer Con
Curis Provides First Quarter 2024 Business Update
08:00am, Tuesday, 07'th May 2024
Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
08:00am, Tuesday, 30'th Apr 2024
LEXINGTON, Mass. , April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inh
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
09:46am, Friday, 05'th Apr 2024
Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:30am, Friday, 05'th Apr 2024
LEXINGTON, Mass. , April 5, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced
